To read the full story, subscribe or sign in.

Rona and Keymed partner to develop siRNA therapies for severe kidney diseases

May 19, 2023

Rona Therapeutics Co. Ltd. and Keymed Biosciences Co. Ltd. formed a collaboration to jointly discover and develop first-in-class siRNA therapeutics for glomerulonephritis, also known as severe kidney diseases.

BioWorld Deals and M&A Genitourinary/Sexual Function China

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2023.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 9, 2023.

Medical cannabis in blister pack of capsules

Zelira’s stock triples as cannabinoid outperforms Lyrica in pain

BioWorld

Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed...

Citing US constitutional violations, Merck the first to challenge the IRA

BioWorld

The question wasn’t if, but when and how, someone would challenge the Medicare negotiation provision laid out in the Inflation Reduction Act (IRA) that was signed...

Reprocell reports mixed results for phase II Stemchymal trial in spinocerebellar ataxia

BioWorld

Regenerative medicine product Stemchymal, an allogeneic adipose-derived mesenchymal stem cell treatment, missed the primary efficacy endpoints in two phase II...

Upgrade your daily dose of biopharma and medtech news

Rona and Keymed partner to develop siRNA therapies for severe kidney diseases